Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 324 across all filing types
Latest filing 2023-10-26 Director's Dealing
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share transactions (disposals) made by an executive (Hong Jong Hui) of Syntekabio. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) as it reports personal share transactions by company insiders.
2023-10-26 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Syntekabio regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자등). It details changes to the investment completion date following the receipt of a building usage permit. Since this is a specific regulatory disclosure regarding capital expenditure and investment updates that does not fit into the other specialized categories like M&A or Share Issues, it is classified as a Regulatory Filing (RNS).
2023-10-04 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Syntekabio regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자등). It details changes to the investment period end date due to construction delays. This type of disclosure regarding capital expenditure and facility investment falls under the category of general regulatory announcements for corporate filings that do not fit into specific financial reporting categories like 10-K or IR, and is best classified as a Regulatory Filing (RNS).
2023-09-27 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Syntekabio regarding a 'New Facility Investment' (신규시설투자등). It specifically details a correction (정정신고) to the investment period end date due to a construction delay. This type of disclosure regarding capital expenditure and facility investment falls under general regulatory filings as it does not fit into specific categories like M&A, dividends, or financial reports.
2023-08-31 Korean
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Syntekabio regarding the exercise of conversion rights (convertible bonds into shares). It details the number of shares to be issued, the conversion price, and the impact on total shares outstanding. This type of filing, which involves changes to the company's capital structure through the conversion of debt into equity, falls under the 'Share Issue/Capital Change' category.
2023-08-16 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '신테카바이오' covering the period from 2023.01.01 to 2023.06.30. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-14 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.